

14th March 2023

- | | |
|---|--|
| <p>(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg</p> | |

Sub: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that the Company and its wholly owned subsidiaries, Cipla (EU) Limited, UK and Meditab Holdings Limited, Mauritius, have entered into a Share Purchase Agreement with Africa Capitalworks SSA 3 on 14th March 2023 for sale of 51.18% stake held in Cipla Quality Chemical Industries Limited (CQCIL), Uganda. Subsequent to the sale, CQCIL will cease to be a subsidiary of the Company.

Details required to be disclosed under the SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 have been provided in Annexure – I to this letter.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Simona Dsouza

Annexure – I

Details required to be disclosed as per SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015

| Sr. No. | Particulars | Details |
|---------|--|--|
| a) | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or subsidiary of the listed entity during the last financial year; | As on 31 st March 2022: <ul style="list-style-type: none"> • Total net worth = USD 44.08 million i.e., 1.62% of Cipla Limited’s consolidated network • Total revenue = USD 75.21 million i.e., 2.57% of Cipla Limited’s consolidated revenue. |
| b) | Date on which the agreement for sale has been entered into; | 14 th March 2023 |
| c) | The expected date of completion of sale/disposal; | The proposed sale is expected to be completed by 31 st May 2023, subject to, inter alia, (i) obtaining regulatory approvals and (ii) completion of conditions precedent as mutually agreed between the parties. |
| d) | Consideration received from such sale/disposal; | Consideration to be received by Cipla (EU) Limited and Meditab Holdings Limited shall be in the range of USD 25-30 million which shall be subject to annualised audited EBITDA of CQCIL for FY23 and other adjustments as agreed between the parties and stated in the Share Purchase Agreement. |
| e) | Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof; | The buyer, Africa Capitalworks SSA 3, is a wholly owned subsidiary of Africa Capitalworks Holdings (“ACW”), an investment management company incorporated in Mauritius. ACW is engaged in providing permanent equity capital and complementary skills to mid-market companies across Sub-Saharan Africa. Neither the buyer nor ACW belong to the promoter/promoter group/group companies. |
| f) | Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”; | No |
| g) | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. | Not Applicable |